Document Detail

Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.
MedLine Citation:
PMID:  10926938     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Intracranial hemorrhage is a serious complication of thrombolytic therapy for acute myocardial infarction, especially among the elderly, but little information exists on estimating risk. Better estimation of risk in individual patients may allow for withholding or using alternate therapies among those at highest risk. METHODS: To quantify the risk and identify predictors of intracranial hemorrhage associated with thrombolytic therapy, we performed a retrospective cohort study using data from medical charts. The study involved nearly all acute-care hospitals in the United States. All Medicare patients discharged with a principal diagnosis of acute myocardial infarction during a 9-month period in 1994 to 1995 were included. The main outcome measure was intracranial hemorrhage among those treated with thrombolytic therapy. RESULTS: The rate of intracranial hemorrhage was 1.43% (455 of 31 732). In a logistic model, age > or =75 years, female, black race, prior stroke, blood pressure > or =160 mm Hg, tissue plasminogen activator (versus other thrombolytic agent), excessive anticoagulation (international normalized ratio > or =4 or prothrombin time > or =24), and below median weight (< or =65 kg for women; < or =80 kg for men) were independent predictors. A risk stratification scale was developed on the basis of these factors: with none or 1 of the factors (n=6651), the rate of intracranial hemorrhage was 0.69%; with 2 factors (n=10 509), 1.02%; with 3 factors (n=9074), 1.63%; with 4 factors (n=4298), 2.49%; and with > or =5 factors (n=1071), 4. 11% (Mantel-Haenszel; P<0.001). CONCLUSIONS: The rate of intracranial hemorrhage in older patients after treatment with thrombolytic therapy exceeds 1%. Readily available factors can identify elderly patients with acute myocardial infarction at high and low risk for intracranial hemorrhage associated with thrombolytic therapy.
L M Brass; J H Lichtman; Y Wang; J H Gurwitz; M J Radford; H M Krumholz
Related Documents :
8557278 - Signal-averaged electrocardiography in survivors of first acute myocardial infarction: ...
1561998 - Milwaukee prehospital chest pain project--phase i: feasibility and accuracy of prehospi...
11790268 - Highlights of latest american college of cardiology and american heart association guid...
2115538 - Reinfarction after thrombolytic therapy for acute myocardial infarction followed by con...
1515448 - Accelerated graft coronary artery disease: diagnosis and prevention.
16928488 - Long-term survival of patients after coronary artery bypass graft surgery: comparison o...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  31     ISSN:  0039-2499     ISO Abbreviation:  Stroke     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-08-29     Completed Date:  2000-08-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1802-11     Citation Subset:  IM    
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT 06520-8018, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Cohort Studies
Fibrinolytic Agents / adverse effects*
Intracranial Hemorrhages / chemically induced*,  epidemiology
Myocardial Infarction / drug therapy*
Retrospective Studies
Risk Factors
Survival Rate
Thrombolytic Therapy / adverse effects*
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling.
Next Document:  Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppl...